Explore › Condition › Atherosclerotic cardiovascular disease risk estimator plus
Condition

Atherosclerotic cardiovascular disease risk estimator plus

Also known as: Atherosclerotic cardiovascular disease risk estimator plus Atherosclerotic cardiovascular disease risk estimator plus (assessment scale) atherosclerotic cardiovascular disease; intellectual/developmental disabilities atherosclerotic cardiovascular disease; type 2 diabetes CVD ASCVD T2D
21 findings 2 papers 12 related entities View in graph →

Related entities

interventions
Cardiorespiratory Fitness4 Statins1 Compound beta-blockers1 Antiplatelet therapy contraindicated1
outcomes
Composite ASCVD events3 Statin therapy1 Beta blocker therapy declined1 Antiplatelet therapy contraindicated1 composite ASCVD events1
populations
Type 2 Diabetes Patients4
studys
PMC81766534 PMC80096953

Findings (50)

None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →

Papers (2)